Kunkel Lori Anne
SEC Form 4 insider trading activity
Kunkel Lori Anne has filed 5 SEC Form 4 filings (8 transaction rows) across 2 companies, including ELVN, ORIC, with disclosures dating back to 2025. 5 of those filings fall inside the rolling window. Most recent filing: Jul 8, 2026.
On the most recent filing, Kunkel Lori Anne is listed as Director at Enliven Therapeutics, Inc. Inside the rolling window, Kunkel Lori Anne reported no open-market purchases and 2 open-market sales totaling $850K in ELVN. The largest disclosed transaction in the window is a sale of 10,000 ELVN shares on Jul 6, 2026, worth $505K.
Companies traded
Other insiders at ELVN
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$850K
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Kunkel Lori Anne made?
Kunkel Lori Anne has filed 5 SEC Form 4 filings (8 transaction rows) across 2 companies, including ELVN, ORIC since 2025.
Which companies does Kunkel Lori Anne trade?
Kunkel Lori Anne has filed SEC Form 4 disclosures for 2 companies, including ELVN, ORIC.
When was Kunkel Lori Anne's most recent SEC Form 4 filing?
Kunkel Lori Anne's most recent SEC Form 4 filing on Tracefour is dated Jul 8, 2026.
What is Kunkel Lori Anne's total buy and sell value in the current window?
Inside the rolling retention window, Kunkel Lori Anne bought $0 and sold $850K based on SEC Form 4 filings.
What was Kunkel Lori Anne's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,000 ELVN shares on 2026-07-06, worth $505K, per SEC Form 4 filings.